<DOC>
	<DOCNO>NCT02763839</DOCNO>
	<brief_summary>The purpose study investigate tolerability , pharmacokinetic profile BIA 3-202 metabolite , pharmacokinetic pharmacodynamic interaction 4 different single dos BIA 3-202 ( 50 mg , 100 mg , 200 mg 400 mg ) single dose standard levodopa 100 mg/carbidopa 25 mg ( Sinemet® 25/100 ) adult male female healthy volunteer .</brief_summary>
	<brief_title>Pharmacokinetic-Pharmacodynamic Interaction Between Four Different Single Doses BIA 3-202 Single Dose Levodopa/Carbidopa ( 100/25 mg )</brief_title>
	<detailed_description>This single centre , double-blind , randomise , placebo-controlled , single-graded-dose , crossover study five single-dose treatment period . The washout period dose 15±2 day . For five treatment period , volunteer admit UFH day treatment day . On treatment period , pre-dose assessment complete , BIA 3-202/Placebo administer concomitantly dose Sinemet® 25/100 post-dose assessment complete . Subjects discharge 30 h post-dose . Subjects attend five treatment period receive different dose BIA 3-202 placebo treatment period .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Carbidopa</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<mesh_term>Carbidopa , levodopa drug combination</mesh_term>
	<criteria>Male female subject age 18 45 year , inclusive . Subjects body mass index ( BMI ) 19 28 kg/m2 , inclusive . Subjects healthy determine pre study medical history , physical examination , 12 lead ECG . Subjects clinical laboratory test acceptable investigator . Subjects negative HBsAg , antiHCV Ab HIV1 HIV2 Ab test screen . Subjects negative drug abuse screen admission . Subjects nonsmoker smoke less 10 cigarette equivalent per day . Subjects able willing give write informed consent . ( If woman ) She childbearing potential reason surgery , childbearing potential , use one follow method contraception : double barrier , intrauterine device abstinence . Subjects conform inclusion criterion , OR Subjects clinically relevant history presence respiratory , gastrointestinal , renal , hepatic , haematological , lymphatic , neurological , cardiovascular , psychiatric , musculoskeletal , genitourinary , immunological , dermatological , connective tissue diseases disorder . Subjects clinically relevant surgical history . Subjects clinically relevant family history . Subjects history relevant atopy . Subjects history relevant drug hypersensitivity . Subjects history alcoholism drug abuse . Subjects consume 28 unit alcohol week . Subjects significant infection know inflammatory process screen and/or admission . Subjects acute gastrointestinal symptom time screen and/or admission ( e.g. , nausea , vomit , diarrhoea , heartburn ) . Subjects acute infection influenza time screen and/or admission . Subjects use prescription drug within 4 week first dose . Subjects use oral contraceptive counter medication exclude oral routine vitamin include mega dose vitamin therapy within one week first dose . Subjects use investigational drug and/or participate clinical trial within 3 month first admission study . Subjects previously receive BIA 3202 . Subjects donate and/or receive blood blood product within previous 3 month prior screen . Subjects vegetarian , vegan and/or medical dietary restriction . Subjects could communicate reliably investigator . Subjects unlikely cooperate requirement study . ( If woman ) She pregnant breastfeeding . ( If woman ) She childbearing potential use approve effective contraceptive method use oral contraceptive . Subjects unwilling unable give write informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Parkinson 's disease</keyword>
	<keyword>Nebicapone</keyword>
</DOC>